$100+ Billion spent on myriad of acquisitions across Pharma and Biotech industries in H1 2018
Lloyd Price
JULY 5, 2018
As BioSpace noted when the deal was announced, Takeda will also take on a significant amount of debt through the deal, sending the price tag closer to $80 billion when that amount is included. Akebia’s vadadustat is in Phase III trials for CKD patients with anemia. The deal will help open U.S.
40 
Let's personalize your content